#USA #Chicago #regenerative medicine #Amphix Bio #Peptide Therapy

Amphix Bio Secures $12.5 Million Seed Funding to Advance Peptide Drug Development

Amphix Bio, a biotech company specializing in the development of new peptide-based therapies, has announced the initial closing of a seed financing round, raising $12.5 million. This funding is aimed at propelling their lead therapeutic candidates towards human clinical trials, particularly focusing on neurological conditions that currently have limited treatment options.

The recent funding round marks a significant milestone for the company, increasing their total financial backing to $18 million, which includes both dilutive and non-dilutive funding. The investment comes from a syndicate of mission-driven investors who share a commitment to delivering innovative therapies that address high unmet medical needs.

Amphix Bio’s pioneering efforts revolve around creating a novel class of peptide therapeutics that target neurological injuries, neurodegenerative diseases, and musculoskeletal disorders. At the core of this innovation is the Supramolecular Therapeutic Peptide (STP) platform, which utilizes assemblies consisting of thousands of molecules. This engineered approach enhances the activation of cell receptors more effectively than conventional drugs, offering the potential for improved therapeutic outcomes.

The STP platform, cultivated through over two decades of research led by co-founder Dr. Samuel Stupp from Northwestern University, boasts a modular structure. This allows for the integration of peptide modifications with a proprietary sequence library, optimizing the properties of various therapeutic candidates.

Nick Sather, PhD, co-founder and CEO of Amphix Bio, expressed pride in the investors on board, highlighting their strong belief in the commercial viability of the peptide platform. He stated, “We are proud to have assembled a group of experienced investors who are confident in our approach and trajectory. They see the immense commercial potential of our platform and are aligned with our mission of developing regenerative therapies that restore function for patients.”

The recently secured funding will propel Amphix Bio forward, primarily towards the initiation of clinical trials for their lead candidates. These lead candidates are centered around two products that have recently achieved regulatory milestones. One of these, AMFX-200, has been designated as an Orphan Drug by the U.S. FDA for the treatment of acute spinal cord injury (SCI). Furthermore, the company has received valuable feedback from a Type C meeting with the FDA regarding the design of preclinical safety studies and clinical trials.

The other promising product, named AMFX-100, has received Breakthrough Device Designation from the FDA for treating degenerative disc disease. Such advancements not only allow for the progression of the lead programs but also lay the groundwork for expanding the peptide platform technology into treatments for additional diseases.

Looking forward, Amphix Bio’s pipeline is intricately designed to cater to various neurological and neuroinflammatory conditions, including chronic spinal cord injury, ischemic stroke, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).

Amphix Bio was established as a spin-off from Northwestern University in Chicago, Illinois, in 2021. The company is firmly rooted in developing a groundbreaking platform technology that modifies the body’s immunological response and triggers regenerative processes, aiming to restore functions lost due to injury, disease, or aging. Their therapies are developed to initiate targeted signaling pathways while simultaneously forming biological scaffolds that support repair and recovery. The overarching goal of Amphix Bio is to extend the human healthspan — that is, the duration individuals can enjoy active, fulfilling lives.

For more information about Amphix Bio and their innovative therapies, please visit their official website at www.amphixbio.com.